Nov 16th: Wide Genetic Testing for Lynch Syndrome Cost Effective « AACR News telephone conference Nov 18th ET U.S./Canada

The American Association for Cancer Research will host a teleconference on these findings on Thursday, Nov. 18, 2010, at 3:00 p.m. ET. Reporters and other interested parties can participate by using the following information:

• Dial-in (U.S. and Canada): (888) 282-7404
• Dial-in (International): (706) 679-5207
• Access Code: 20084557

Updated Oct 2010: Genetic Syndromes - Genetics of Breast and Ovarian Cancer - National Cancer Institute

Major Genes

Introduction

BRCA1
BRCA2
BRCA1 and BRCA2 Function

Mutations in BRCA1 and BRCA2
Variants of uncertain significance

Prevalence and Founder Effects

Models for Prediction of the Likelihood of a BRCA1 or BRCA2 Mutation

Penetrance of Mutations
Cancer risk in individuals who test negative for a known familial BRCA1/2 mutation
Breast and ovarian cancer risk in breast cancer families without detectable BRCA1/2 mutations

Population Estimates of the Likelihood of Having a BRCA1 or BRCA2 Mutation

Role of BRCA1 and BRCA2 in Sporadic Cancer

Genotype-Phenotype Correlations

Pathology/Prognosis of Breast Cancer
BRCA1
BRCA2
Contralateral breast cancer in BRCA mutation carriers

Pathology/Prognosis of Ovarian Cancer
Pathology
Prognosis

Other Rare Breast and Ovarian Cancer-Associated Syndromes
Li-Fraumeni syndrome
Cowden syndrome
Peutz-Jeghers syndrome

Families and Scientists Gather to Discuss Research and Treatment for Li-Fraumeni Syndrome

An archived video of the full meeting is available through the NIH Videocast Web site.

"...Li-Fraumeni syndrome was first described in a 1969 publication in the Annals of Internal Medicine by Dr. Joseph F. Fraumeni, Jr., the director of DCEG, and his colleague Dr. Frederick P. Li. They described four families in which several members developed a wide variety of cancers as children or young adults. Many of the patients had multiple primary tumors, most notably breast cancer, soft tissue and bone sarcomas, brain tumors, adrenocortical neoplasms, and acute leukemia. Subsequent studies identified additional families that met the classic criteria for LFS. Other families had similar but less pronounced aggregations of cancer and were classified as Li-Fraumeni-like (LFL)...."

(OVA1 ovarian cancer blood test) Vermillion Inks New Agreement with Quest Diagnostics - GLG News

Firm prepares for cancer patents hearing - The New Lawyer (BRCA patents) - Australia

Canary Foundation of Canada

Canary Foundation - Ovarian Cancer Program

Figure 1: Stage at Diagnosis

Figure 2: Survival by Stage of Diagnosis

Expansion of cancer care and control in countries of low and middle income: a call to action : The Lancet

Note: includes a number of easy to read charts/comparisons

Editorial: Cancer: the revolution has begun : The Lancet

BRCA | prIME Oncology conference notice Tel Aviv, Israel Nov 18-19th

Advancing Ethical Research Conference - December 2010

abstract + Free Full-Text (2010) Familial Pancreatic Cancer (includes discussion regarding BRCA/Lynch Syndrome/FAMMM and others)

Abstract: Pancreatic cancer’s high mortality rate equates closely with its incidence, thereby showing the need for development of biomarkers of its increased risk and a better understanding of its genetics, so that high-risk patients can be better targeted for screening and early potential lifesaving diagnosis. Its phenotypic and genotypic heterogeneity is extensive and requires careful scrutiny of its pattern of cancer associations, such as malignant melanoma associated with pancreatic cancer, in the familial atypical multiple mole melanoma syndrome, due to the CDKN2A germline mutation. This review is designed to depict several of the hereditary pancreatic cancer syndromes with particular attention given to the clinical application of this knowledge into improved control of pancreatic cancer.
Keywords: phenotypic and genotypic heterogeneity; high mortality; genetic counseling; biomarker paucity; FAMMM syndrome; Li-Fraumeni syndrome; Lynch syndrome; pancreatic cancer

Management of Unexplained Symptoms in Survivors of Cancer — JOP abstract

M.R.I.’s Help Women at High Risk for Breast Cancer - NYTimes.com